Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphoglycerate mutase 1 pseudogene 3 (PGAM1P3) is classified as a processed pseudogene in the human genome, generated by retrotransposition of the mRNA from its parental gene, PGAM1, which encodes the glycolytic enzyme phosphoglycerate mutase 1. PGAM1P3 lacks the ability to encode a functional protein; while some processed pseudogenes can occasionally retain coding potential, there is no experimental evidence for protein expression from PGAM1P3[2][5][3]. It does not participate in enzymatic activity, signaling, or cellular regulation, nor is it involved in disease pathogenesis or therapeutic modulation. Its relevance in molecular biology is limited to genomic studies and evolutionary research, rather than direct biomedical or pharmacological applications[2][5][6][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphoglycerate mutase 1 pseudogene 3 (PGAM1P3).